Tau, which is induced by IDH mutations, inhibits the EGFR/NF-kB/TAZ axis and impairs the mesenchymal/pericyte-like transformation of glioma cells, normalizing the vasculature and impairing tumor aggressiveness.
INTRODUCTION
Diffuse gliomas are classified and graded according to histological criteria. They include low and intermediate-grade gliomas (herein called Lower-Grade Gliomas, LGG), which encompass World Health Organization (WHO) grades 2 and 3, and the highly aggressive WHO grade 4 glioblastomas (GBM), with 5-year survival rates of 5%. They are categorized based on the increments in cellular atypia and mitotic activity. On top of that, GBM are characterized by the specific presence of areas of necrosis and robust neoangiogenesis, being considered one of the most vascularized cancers.
LGG are more indolent tumors although many of them progress into secondary GBM, albeit at highly variable intervals, with survival rates that goes from 1 to 15 years (1) .
Unfortunately, little is known about the factors that drive this transition from LGG to GBM.
A big effort has been made in the last two decades in order to characterize the genetic modifications associated with gliomas. Some of them have been incorporated into the novel WHO classification. Particularly, the identification of mutations in the IDH1/2 (Isocitrate dehydrogenase 1/2) genes, which are associated with a more favorable prognosis in gliomas (2) , is common now in the routine clinical practice. IDH1/2 mutated proteins induce the accumulation of the oncometabolite, 2-D-hydroxyglutarate (2-HG), which competes with the-ketoglutarate (-KG) produced by the wild-type IDH enzymes and blocks TET (Ten Eleven Translocation)-mediated DNA demethylation.
This process generates a CpG island methylator phenotype (G-CIMP), which is associated with a general suppression of gene expression (3) . Moreover, 2-HG inhibits histone demethylases, which further contribute to this phenotype (4) . By contrast, wildtype IDH1 promotes the metabolic adaptation of GBM cells to support aggressive growth (5) . Therefore, it has been proposed that the balance between wild-type and mutant IDH1/2 function determines the clinical outcome of gliomas, including their sensitivity to radiation and chemotherapy (6) .
Within the new subclasses of high grade gliomas (proneural (PN), classic (CL) or mesenchymal (MES)), IDH1/2 mutations are accumulated in the first group, which is enriched in secondary GBM and includes tumors with a better clinical prognosis (7) . By contrast, mutations in EGFR (Epidermal growth factor receptor) accumulate in the CL and MES subtypes. This gene is mutated and/or amplified in a large percentage of diffuse gliomas and it has been associated with proliferation and survival, as well as with the invasive properties of glioma cells (7;8) .
Several cytoskeletal proteins have been involved in tumor progression. Tau, encoded by the gene MAPT (Microtubule-associated protein tau), is well-known for its relevance in Alzheimer´s disease (AD) although it is also expressed in healthy brains, where it controls neural development and synaptic transmission (9) . In addition, Tau and other microtubule-stabilizing agents like taxanes modulate protein and organelle trafficking (10, 11) , which could be relevant for cancer cells. Interestingly, a possible comorbidity of dementias and GBM had been suggested (12) , which led us to perform a bioinformatic analysis. We found that Tau (MAPT), among other genes related to neurodegeneration, is expressed in gliomas, where it seems to correlate negatively with tumor progression (Gargini et al., Front. Aging Neurosci., in press). Based on these data, we decided to conduct a more comprehensive characterization of Tau in this deadly pathology. Here we show that the expression of this protein depends on the genetic status of IDH1/2, being enriched in LGG and PN gliomas, where it hinders tumor progression. Mechanistically, we have found that Tau inhibits the EGFR-NF-kB-TAZ signaling pathway, provided that no EGFR mutations are present. By blocking this cascade, it impedes the plasticity of the tumor cells and their capacity to generate mesenchymal/pericyte-like cells, which participate in the processes of angiogenesis and neo-vascularization. As a consequence, Tau favors the normalization of the glioma´s vasculature and hampers tumor progression. Therefore, we propose a novel role for Tau in gliomas, acting downstream of IDH mutations to orchestrate the vascular phenotype and the aggressiviness of these tumors.
RESULTS

High levels of Tau (MAPT) correlate inversely with glioma aggressiveness
The in silico analysis of the glioma TCGA data set showed that the level of Tau (MAPT) decreases as the tumor grade increases, at least in astrocytomas ( Fig. 1A, and fig. S1 A and B). In agreement with this observation, a higher expression of the Tau (MAPT) gene was associated with an increased overall survival of glioma patients ( Fig.   1B and C, fig S1C to F). These results confirmed our previous data (Gargini et al., Front. Aging Neurosci., in press) and prompted us to perform an immunohistochemical (IHC) staining on glioma samples, which showed that Tau protein is clearly expressed in the cytoplasm of tumor cells, with a very different pattern to the one observed in normal tissue (NT) ( Fig. 1D, and fig. S1G ). Moreover, we found high levels of Tau in a subset of the gliomas analyzed by Western Blot (WB) (Fig. 1E ). The quantification of the IHC staining ( Fig. 1F ) and the WB (Fig. 1G ) confirmed that Tau protein is clearly enriched in
LGG compared to GBM. As this accumulation could explain by itself the survival data ( Fig. 1B and C) , we decided to dissect out the effect of Tau expression in LGG and GBM by using separated TCGA cohorts. Fig. 2A and B show that the transcript level of Tau correlates with an increased overall suvival in both sets of patients. Similar results were obtained when we meassured Tau by RT-PCR analysis in our own GBM cohort ( Fig.  2C ). Collectively, these results support the idea that Tau expression is associated with a less aggressive behavior of gliomas, independently of the tumor grade. Furthermore, we found a marked decrease in the expression of Tau in disease free vs progressed tumors ( Fig. 2D ). To confirm these observations we performed a longitudinal IHC quantification of Tau in primary LGG and their recurrent paired samples. Remarkably, we found a consistent decrease in Tau expression in those tumors that had progress into a more aggressive phenotype ( Fig. 2E) , which was not observed when there was no change in the histological classification of the recidives (Fig. 2F ). These results suggest that Tau downregulation must be important for the tumors to relapse after surgical resection, which is a critical step in the mortality related to this pathology. To further asses the presence of Tau in glioma cells and its participation in tumor aggressiveness we analyzed its expression in a panel of patient-derived-xenografts (PDX), obtained from GBM surgeries and grown subcutaneously, devoided of any trapped neurons. As we had previously observed in tumor samples ( Fig. 1E ), the amount of Tau protein in the PDXs was highly variable ( Fig. 2G, and fig. S2A ). It is important to remark that in those tumors with high levels of the protein, a big percentage of GFAP cells were positive for Tau staining ( fig S2A and fig. S2B ), further supporting the specific expression of Tau in glioma cells.
In order to know if Tau levels affect tumor behavior, we injected some of the PDX cells into the brains of immunodeficient mice. We observed that those primary cell lines with higher levels of Tau (measured by qRT-PCR with human specific primers ( Fig. 2I ) grew significantly slowlier ( Fig. 2H ). Moreover, the overexpression of this gene in a Taudeficient glioma cell line (12o15) delayed tumor formation ( Fig. 2J and fig. S2C ), whereas its downregulation in Tau-enriched cells (12o02) clearly increased their aggressive behavior ( Fig. 2K and fig. S2D ). Altogether, our results confirm that Tau is expressed in the tumor cells of several gliomas, especially in the less aggressive ones. Additionally, they suggest that Tau could be playing an active role as an inhibitor of tumor progression. 
The expression of Tau (MAPT) in gliomas is regulated by IDH function
We analyzed the genetic background of gliomas in relation to the levels of Tau (MAPT) and we found that IDH1 mutations accumulate in high-Tau gliomas (Fig. 3A ).
This correlation was validated using a Volcano Plot analysis ( Fig. 3B ). Furthermore, Tau protein was detected in the majority of tumor cells that express the most common IDH1 mutation (R132H) ( fig. S3A and B). This observation confirms that the protein is truly expressed in the tumor cells and not only in the trapped neurons. We then quantified the amount of Tau IHC staining in wild-type and mutant IDH gliomas and we found a clear enrichment of high and medium stained sections in the second group (Fig. 3C ). These results suggest that there is a strong correlation between the presence of IDH mutations and the expression of Tau. This seems to be independent of the tumor grade as we found higher levels of Tau in IDH mutant compared to IDH wild-type tumors in the GBM ( fig. S3C ), as well as in the LGG ( fig. S3D ) TCGA cohorts. In order to confirm the relationship between Tau and IDH mut, we analyzed a recently published glioma model, in which IDH1 wt or IDH R132H had been expressed in an ATRX mutant background (13) . As expected, there was a clear delay in the tumor growth after the expression of mutant IDH1 ( Fig. 3D ). Moreover, when we dissected out the intracranial tumors we measured a clear increase in Tau protein levels in the mutant compared to the wild-type allografts ( Fig. 3E ). These results suggest that the expression of Tau in gliomas is induced by mutant IDH proteins. The G-CIMP phenotype, which is associated with the presence of IDH mutations, is supposed to block the transcription of many genes. However, it also activates certain others, especially those involved in the tumorigenesis of LGG (like the PDGFRA (Platelet Derived Growth Factor Receptor Alpha) oncogene) through the disruption of the repressive structure of the CTCF insulator protein (14) . Interestingly, we observed an increased expression of Tau in the G-CIMP GBM subtype ( fig. S4A ), as well as a significant correlation between the amount of Tau (MAPT) and PDGFRA mRNAs in the TCGA samples ( fig. S4B ). These results suggest that Tau promoter might be controlled by the epigenetic changes induced by IDH mutations. To test this theory, we first analyzed the presence of CpG islands in the Tau (MAPT) promoter region by using the xena genome browser. We identified three of them in the 5´region of transcription initiation site ( fig. S4C ), which correlate with the sites previously described (15) . Using epigenetic data from the TCGA (LGG cohort) we compared the methylation of the whole promoter region in mutant vs wild-type IDH tumors. We observed an increased methylation in CpG:26 ( and E) in the mutant tumors. However, when we analyzed the ChIP-seq data of the CTCF binding to the different clusters, we observed that only the binding to the CpG:26 site was lost in the IDHmut tumors ( Fig. 3G ). In order to obtain an independent confirmation of the epigenetic upregulation of Tau (MAPT) in response to mutant IDH, we treated primary GB cells with 2-HG and we observed a dose-dependent accumulation of its mRNA ( Fig. 3H ), an effect that was reversed in the presence of azacytidine (AZA) ( Fig. 3I ). In summary, these results strongly suggest that the increase in the methylation of the CpG:26 region, induced by IDH mutant proteins, changes the chromosomal insulator topology and the binding of CTCF to the Tau promoter, activating its transcription.
It is well known that IDH1/2 mutations define a distinct subset of gliomas with a better outcome. By contrast the expression of IDH wild-type in LGG and GBM defines a subgroup with poorer prognosis ( fig. S4F ). Interestingly, we found an inverse correlation between the expression of wild-type IDH1 and Tau on the TCGA (Fig. 3J ) and the Rembrandt (Fig. 3K) cohorts, suggesting that the balance between wild-type and mutant IDH expression determines the epigenetic regulation of the Tau promoter.
Tau opposes EGFR signaling in gliomas
The results presented here indicate that Tau is highly expressed in a subset of gliomas, especially in IDH mutant tumors, where it seems to impair tumor aggressiveness. To gain insight into the mechanism behind this behavior, we performed a DAVID gene analysis of the pathways co-upregulated with Tau in gliomas. As 
Microtubule stabilizators like Tau and EpoD favor the degradation of wild-type EGFR
When we analyzed the dissected tumors after Tau overexpression we observed that the levels of phospho-EGFR were attenuated in SVZ-EGFRamp/wt tumors ( Previous results from our group have demonstrated that, as a result of Tau function, stabilized microtubules become heavily acetylated through the inhibition of HDAC6 (histone deacetylase 6). In fact, the increase in tubulin acetylation can serve as a readout of Tau expression (16) . Moreover, it has been proposed that this acetylation promotes the subsequent degradation of EGFR due to changes in the microtubuledependent endocytic machinery (17) . In agreement with these published data, we observed high levels of acetylated tubulin in Tau overexpressing gliomas (mouse or human), which were paralled by a strong decrease in the amount of total EGFR protein ( Fig. 5E ). Interestingly, the downregulation of EGFR protein can be observed in vitro after Tau overexpression, and this effect was reverted in the presence of MG132 (proteasome inhibitor) or chloroquine (lysosome inhibitor) ( Fig. 5F ). Collectively, these results suggest that Tau impairs EGFR signaling through the stabilization of the microtubules and the subsequent alteration of the receptor trafficking, which leads to its degradation. To validate this hypothesis we treated RG1(EGFRamp)-injected mice with a Taxol derivative, Epothilone D (EpoD). This kind of components can stabilize the microtubules as well. In fact, they compete with Tau for the same tubulin-binding site.
EpoD in particular has been proved to reach the brain and revert some of the axonal defects of a Tau loss-of-function model (18) . Systemic treatment with EpoD significantly delayed RG1 tumor formation ( Fig. 5G ) and reduced the amount of phospho-EGFR in the tumors ( Fig. 5H and I) without changing the levels of Tau protein (Fig. 5H ). This was accompanied by a strong downregulation of the levels of EGFR and a clear increase in the amount of acetylated tubulin ( Fig. 5H and I). Altogether, our data support the notion that the microtubule-related function of Tau is responsible for its effect on EGFR signaling and tumor growth in gliomas. Moreover, they suggest that taxol derivatives could reduce the aggressiviness of gliomas. In fact, we observed that EpoD treatment made RG1 tumors more sensitive to chemotherapy ( Fig. 5J ) so there could be a therapeutic opportunity for these compounds to be used in glioma patients. 
Tau blocks the mesenchymalization of EGFRamp/wt glioma cells.
The bioinformatic analysis showed that the levels of Tau (MAPT) correlate positively with the PN signature while they exhibit a strong inverse correlation with the MES expression profile of gliomas ( Fig. 6A, and fig. S6A to F). In addition, we observed that Tau expression inversely correlates with the NF-κB (Nuclear factor kappa-lightchain-enhancer of activated B cells) and the inflammatory pathways, but not with other signatures, like those associated with hypoxia or PDGFRα ( Fig. 6A and B) . These in silico observations were confirmed by the WB analysis of RG1 (EGFRamp) xenografts, which showed that overexpression of Tau induces a clear inhibition of the NF-κB subunit phosphorylation, as well as a strong reduction in the protein level of TAZ, a master regulator of the MES phenotype (19) (Fig. 6C and D) . Similar results were obtained in the WB analysis of 12o15 xenografts ( Fig. 6E and F) , a primary cell line that overexpresses the receptor in the absence of gene amplification (20) . However, Tau did not change the expression of other MES genes ( Fig. 6G) and it had no effect on TAZ expression or NF-B activation in EGFRmut tumors, where there was no inhibition of the receptor upon Tau induction ( fig. S6G ). These data suggest that EGFR signaling induces the MES features in gliomas, which can be impaired by Tau, provided that no additional mutations in the receptor are present.
Tau overexpression also induced the expression of OLIG2 (Fig. 6H) , a transcription factor that is frequently used as a bona fide PN marker (21) . Moreover, the IF analysis of RG1 gliomas confirmed that Tau represses the nuclear expression of TAZ, whereas it induces the nuclear expression of OLIG2 in the tumor cells ( Fig. 6I) . These data were confirmed by RT-PCR analysis of human samples ( Fig. 6J and K) , and by in silico studies ( fig. S6H ), which showed that Tau correlates inversely with TAZ and positively with OLIG2 expression. Altogether, our results indicate that Tau induces a change in the glioma phenotype, repressing MES regulators and inducing PN promoters in the tumor cells through the regulation of the EGFR/TAZ/NF-kB pathway. It is important to remakr that Tau did not change the tumor burden of RG1 cells in the presence of TAZ overexpression ( Fig. 6L and M) , which suggest that Tau represses the growth of EGFRamp/wt glioma growth by blocking the plasticity of tumor cells and the appearance of mesenchymal features. Previous results from our group and others have shown that, in comparison with PN cancer stem cells (CSCs), MES CSCs are more capable of glioma initiation, probably associated with their increased angiogenic capacity (22, 23) . In agreement with this observation, the overexpression of Tau in RG1 cells impaired their capacity to form subcutaneous xenografts ( fig. S7A and B ). Furthermore, we found that most of the genes upregulated with TAZ in gliomas were associated with angiogenesis and tumor vasculature ( fig. S7C to F) . Particularly, we noticed that markers of pericytes, which are considered as perivascular MES stem cells (24) , were among the genes which correlated better with TAZ in gliomas ( fig. S7G and H) . In order to examine if this transcription factor could modulate the function and/or the number of mural cells we induced the expression of shTAZ in RG1 cells and we performed an ortothopic in vivo experiment. As expected, the knock down of this gene clearly reduced the aggressiviness of the tumors (Fig. 6N) .
Moreover, we observed a significant inhibition of the expression of several pericyte markers in RG1 shTAZ compared to control tumor samples ( Fig. 6O ). It is worth mentioning that TAZ seems to regulate peryctic differentiation in a cell-autonomous way, as we also observed a reduction of these markers after the in vitro expression of shTAZ in RG1 and 12o15 cells ( Fig. 6P to R) . These results are in accordance with some recent publications showing that most of the pericytic functions in GBM are performed by the highly plastic CSCs, which undergo a transdifferentiation process, acquiring mesenchymal and mural cell features (25) (26) (27) .
Tau reduces the amount of tumor-derived-pericytes and normalizes the vasculature of EGFRamp gliomas
Our results indicate that Tau impairs the mesenchymalization of glioma cells by blocking the expression of TAZ, which is induced in response to EGFR activation.
Moreover, we could hypothesize that, as a result of this inhibition, there is an important blockade of the capacity of the tumor cells to transdifferentiate into pericytes. Therefore, we decided to analyze the vascular component of the tumors after the overexpression of Tau in RG1 (EGFRamp) cells. We observed a marked decrease in the number of SMA and CD248 positive cells (Fig. 7A ), together with a significant inhibition of the expression of human pericytic markers, in Tau-expressing tumors (Fig. 7B) We had previously noticed the lack of hemorrhages in EGFRamp tumors overexpressing Tau, an event that was frequent in control tumors (Fig. 7H ). In parallel, we observed a reduction in the extravasation of IgG after Tau overexpression (Fig. 7I) .
These observations suggest that tumors that overexpress Tau present a less aberrant tumor vasculature, with an increase in the intregrity of the blood brain barrier (BBB). In agreement with this hypothesis, Tau induced a clear reduction in the levels of Ang2 (Angiopoietin 2) ( Fig. 7J) , a key regulator of angiogenesis that has been associated with vascular abnormalities in glioma, acting as an antagonist of Ang1 (29) . In fact, we observed a significant decrease in the Ang2/Ang1 ratio after Tau overexpression ( In order to confirm the relevance of the tumor-derived-pericytes in the growth of EGFRamp gliomas, we downregulated CD248 expression in RG1 cells. CD248, also called endosialin, aids in supporting tumor microvasculature and it is expressed in pericytes, especially in malignant solid tumors, including high-grade gliomas (26, 30) . We picked the most effective shRNA sequences ( fig. S8F ) and we injected the interfered cells into the brains of immunodeficient mice, in the presence of normal host pericytes.
We observed a significant delay in tumor growth after CD248 downregulation (Fig. 7L) .
Moreover, the inhibition of CD248 in the tumor cells reduced the expression of other pericytic markers in vitro ( fig. S8G ) and in vivo (Fig. 7M) . These results suggest that CD248 is a key player in the transdifferentiation of tumor cells into pericytes. On top of that, tumors formed after CD248 downregulation showed a reduction in the extravasation of IgG (Fig. 7N) as well as a decreased Ang2/Ang1 ratio (Fig. 7O) , wich further supports the hypothesis that the depletion of tumor-derived-pericytes (at least in EGFRwt/amp tumors) normalizes the glioma vasculature and reduces the aggressiviness of this type of cancer.
Tau expression is a surrogate marker of the less aggressive vascular behavior of gliomas
The data presented so far place Tau at the boundary between the most common genetic alterations of gliomas (those that affect IDH1/2 and EGFR) and the regulation of the tumor microenvironment, in particular the vascular phenotype. In order to translate the results obtained in mouse models into the clinical settings, we used our own cohort of patient´s samples (RT-PCR analysis) and the data from the TCGA (in silico analysis).
We divided the tumors into an IDH1 mut (those with higher transcript levels of Tau) and an IDH1 wt group, and we subclasified the second one into High or Low Tau gliomas ( Fig. 8A and B) . First, we confirmed that the inverse correlation between the levels of Tau and the amount of phospho-EGFR was maintained in the human samples (Fig. 8C ).
Moreover, we also observed a significant inverse correlation between the transcript levels of CD248 and the expression of Tau (Fig. 8D and E) , which was confirmed by the IHC analysis of the tumors. The representative images in Fig. 8F evidence the gradual normalization of the vasculature in parallel with the increase in Tau levels (Fig. 8F ).
Furthermore, the quantification of the CD248 score (Fig. 8G) , the amount of CD34 (Fig.   8H ) and the amount of dilated vessels (Fig. 8I) , confirmed the visual differences and reinforced our model, in which Tau expression could function as a surrogate marker of the less aggressive vascular behavior in gliomas. Certainly, patients with such tumors have a much better prognosis, independently of the histological classification, and they show improved responses to chemotherapy and/or irradiation (31, 32) . Indeed, the re-expression of IDH1 R132H in GBM can reduce tumor growth ( fig. S4F) (13, 33) . However, the molecular basis for the tumor-suppressor functions of IDH mutations are unclear. Here, we have identified Tau, a known microtubule stabilizer, as a new epigenetic target of IDHmut in gliomas. Based on our results we can propose that these mutant enzymes, acting through the increase in Tau expression, favor the normalization of the vasculature and impede the progression of the disease (fig. S9 ). In fact, Tau downregulation induces a dramatic increase in tumor burden in the orthotopic xenografts. Moreover, the longitudinal analysis of a set of paired samples showed that Tau expression decreases as LGG evolve into higher grade lesions. Interestingly, IDH1/2 status seems to be consistent during glioma progression (34, 35) , suggesting that some other mechanism is inhibiting Tau transcription in the recurrent tumors. One possible explanation would be that an increase in the levels of wild-type IDH protein in the recidives could impair Tau expression, as it happens in the mouse xenografts (Fig. 4D ). Indeed, it has been recently shown that the non-mutated IDH1 is upregulated in primary GBM in comparison with secondary GBM or LGG, where it promotes aggressive growth and therapy resistance (5) .
From the moment that IDH1/2 mutations were identified in gliomas, it seemed clear that they represent early events in the process of tumorigenesis (36) . A decade later we know that these proteins induce important metabolic and epigenomic changes, which could explain their oncogenic properties (4, 13, 14, 37, 38) . Consequently, a plethora of inhibitors have been developed to block IDHmut function in different cancers. Indeed, some of them have shown anti-tumor acitivty in mouse glioma models (39) and they have been approved to be tested in IDHmut patients (40) . However, the tumor-suppressor functions of these proteins in gliomas, including the vascular normalization that we have described here, could represent a severe pitfall for these approaches. In fact, the treatment with IDHmut inhibitors has been associated with a radioprotective effect (41) and a decreased sensitivity to cisplatin (42) . Regarding IDHwt gliomas, our results suggest that microtubule stabilizers could imitate Tau function and reduce the aggressiveness of the tumors, which could render them sensitive to conventional chemotherapy (Fig. 5I) . The same compounds could be tested in combination with IDHmut inhibitors in LGG, in an attempt to impair tumor growth and, at the same time, block the transformation into a more aggressive tumors.
Our results indicate that Tau is a key inhibitor of wild-type EGFR signaling in gliomas. Accordingly, drugs that interfere with microtubule function have been associated with EGFR inactivation in other cancers (43) , as they seem to alter endocytic trafficking (11) . Moreover, it has been shown that microtubule acetylation, which is promoted by Tau function (16) , promotes the degradation of EGFR through changes in the microtubule-dependent endocytic trafficking (17) . We propose that a similar mechanism could be operating in gliomas, but only in the absence of EGFR mutations.
In that sense, there is plenty of literature that suggest that EGFR mutant proteins, especially the vIII isoform, can maintain the signal in the absence of the ligand (44), possibly due to changes in the turnover of the mutant receptor (45) . Moreover, it has been proposed that some of the EGFR downstream targets, like NF-κB, become constitutively activated in GBM after vIII expression (46) . The data presented here further supports that EGFR mutations induce a constitutive activation of NF-κB, which would be unsensitive to microtubule modulators.
Downstream of EGFR/NF-B signaling, we have found that Tau overexpression severely reduced the amount of TAZ in GBM. TAZ is a transcriptional coactivator that play a prominent role in gliomas (47) , controlling the MES signature (19) . Moreover, TAZ is induced by NF-κB activation in gliomas and promotes radio-resistance (19) . It has been recently proposed that TAZ promoter is a direct target of NF-B (48) so Tau could be inhibiting indirectly the transcription of the TAZ gene. However, we cannot discard a possible regulation of the protein stability downstream of EGFR/NF-B signaling.
It is well known that IDH mutant gliomas are characterized by a lesser extent of contrast enhancement than wild-type tumors, even if we only consider GBM (49) .
However, the molecular explanation for this behavior was still missing. Our results show that Tau, acting downstream of IDHmut, could normalize the blood vessels and reduce the BBB leakage. These changes could cooperate or even precede other alterations observed in the TME of IDHmut gliomas, like the absence of microthrombi (50) as well as the decrease in necrosis areas (49) and hypoxia-induced angiogenesis (51) .
Moreover, the immune component and its pro-or anti-tumoral properties could also be affected by the vascular phenotype of IDHmut gliomas (52) , explaining the decrease in the immune infiltrate observed in mouse models and human samples (33) . Future experiments are warranted in order to decipher the participation of Tau in these other phenotypes.
Although cancer and neurodegenerative diseases are considered as opposite phenomena, there could be a positive association between AD prevalence and GBM incidence (12) . In AD and other tauopathies, there is an accumulation of Tau aggregates (gain of toxic function). However, this aggregation of Tau compromises its microtubulestabilising functions (loss of physiological function), favoring the evolution of the pathology. In agreement with the loss-of-function model, we have reported behavioral changes and neurogenesis in aged Tau knockout mice (53) . Interestingly, EMT genes are enriched in the affected areas of AD brains (54) . Moreover, there is an important neurovascular dysfunction at early stages of AD, associated with BBB breakdown and inflammation (55) , which could be linked to pericyte loss (56) . Although there is still missing evidence of the relevance of Tau (especially the astrocytic Tau) in these phenotypes, it is tempting to speculate that the loss of function of this protein could represent a link between the progression of the two types of brain diseases. If this hypothesis is correct, targeting pericytes or the mesenchymal transdifferentiation of the astrocytes could be an interesting therapeutic approach to be tested in several neurological disorders. Moreover, it would be worth studying if AD related drugs could be repurposed to treat brain tumors. In that sense, we have demonstrated that EpoD, a microtubule stabilizing agent that reduces AD pathology in mouse models (18) , slows down in vivo glioma growth without any apparent secondary effect. Another secondgeneration taxane, cabazitaxel, has demonstrated a good anti-glioma activity in preclinical tests (57) and is being evaluated as a novel cytotoxic therapy (NCT01740570, NCT01866449). However, we propose that lower doses of these compounds could imitate the effect of Tau overexpression, reducing the aggressiviness of gliomas with less secondary effects for the patients. By contrast, as they compete for the same microtubule binding site of Tau, high levels of this protein could identify gliomas that would be resistant to taxol derivatives, as it has been shown for other cancers (58) . 
MATERIALS AND METHODS
Human samples
Glioma tissues embedded in paraffin were obtained after patient´s written consent and with the approval of the Ethical Committees of "Hospital 12 de Octubre" (CEI 14/023) and "Hospitales de Madrid" (14.10.632-GHM, 18.12.1337-GHM) (Table S1 and 2).
Human and mouse glioma cells
RG1 cells were kindly donated by Rosella Galli (San Raffaele Scientific Institute). The rest of the human cells (Table S3) cultures from p16/p19 ko mice. The NSCs were obtained as previously described (59) and they were grown in CM. After infection, the cells were injected into nude mice and the tumors that grew were dissociated and established as SVZ-EGFRamp/wt or SVZ-EGFRvIII models. Both models express GFP and luciferase as reporters. These established cell lines (300,000 cells) give rise to gliomas when they are implanted in the brains of nude mice with a 100% penetrance. The average survival is around 62 days for the SVZ EGFR wt/amp model and around 32 days for the SVZ EGFR vIII cells, showing a proliferation rate of more than 10% in SVZ EGFR wt/amp tumors and more than 30 % for SVZ EGFR vIII tumors. Both mouse glioma models, SVZ EGFR wt/amp and SVZ EGFR vIII, showed a complete dependence on EGFR activity, since their growth can be impaired by a tyrosin kinase inhibitor (dacomitinib) (44) . NPA (NRAS, shP53, shATRX) IDH1 wt and NPA (NRAS, shP53, shATRX) IDH1 R132H were provided by Maria G. Castro (University of Michigan) (13) and cultured in CM.
DNA constructs and lentiviral/retroviral production
The lentivirus that encodes the longest wild type isoform of Tau in human brain harboring four repeats and two N-terminal inserts followed by GFP linked by an IRES was a gift from by Prof. Kenneth S. Kosik (UC Santa Barbara). As a control we used a lentivector Temozolomide was dissolved in 1% BSA+PBS. Control animals were treated with these solvents.
Growth curve and sphere formation assay
Glioma cells were infected by the control lentivirus (LV-GFP) or lentivirus directing expression of TAU (LV-TAU-GFP). The tumor spheres were Accumax-dissociated to single cells, and 500/1000 cells of each condition were plated in a p24-well-plate in triplicate. Five days after plating, spheres and cell number were measured.
EGFR degradation experiment
GFP or TAU SVZ EGFRwt/amp cells were grown in stavirng media for 1h and then EGF (100 ng/ml) was added and the cells were incubated in the presence of DMSO, MG132 or Chloroquine for 2h. Then, cells were collected and lysed and subsequently analyzed by western blot, as described below.
Endothelial cell sprouting assay
In order to generate endothelial cell spheroids, 1x10 6 cells of HMBEC were suspended in CM and seeded in nonadherent plates. These spheroids were harvest within 48 hours and embedded into matrigel in 96-well plates with conditioned medium generated for each cell line. After 24 h, sprouting was induced and the number of sprouts for each spheorid were quantified. For the generation of the conditioned media, RG1 (GFP or Tau) were grown during 48 hours in serum-free culture media (DMEM-F12 supplemented with FGF2 (50ng/ml) and penicillin-streptomycin). The medium was filtered with a 70-m filter before use.
In vivo limiting dilution assay
Increasin numbers of RG1 (GFP or TAU) cells were re-suspended in CM and Matrigel (BD) (1:10) and injected subcutaneously injected in nude mice. Animals were sacrificed before tumors reached a 1.5 cm in diameter. The statistical significances were calculated using the Extreme Limiting Dilution Analysis software (http://bioinf.wehi.edu.au/software/limdil/ index.html).
Inmunofluorescent (IF) and Inmunohistochemical (IHC) staining
Slides were heated at 60ºC for 1 hour followed by deparaffinization and hydration, washed with water, placed into antigen retrieval solution (pressure cooking) in 10 mM sodium citrate pH 6.0. Paraffin sections were permeabilized with 1% Triton X-100
(Sigma-Aldrich) in PBS and blocked for 1 hour in PBS with 5% BSA (Sigma), 10% FBS (Sigma) and 0,1% Triton X-100 (Sigma). The following primary antibodies (Table S4) were incubated O/N at 4ºC. The second day, sections were washed with PBS three times prior to incubation with the appropriate secondary antibody ( 
IHC quantification
The IHC score was judged from 0 (no staining) to 3 (Tau staining) or 4 (CD248 staining) on those samples with the strongest positive staining. For the longitudinal analysis of the primary and relapsed tumors we calculated the score of 10 high magnification pictures of each sample. The data depicted in Figure 2e ,f is the average of these 10 pictures. For the quantification of the vasculature, we counted the number of dilated vessels per highmagnification field.
Western Blot analysis
Protein content was quantified using BCA Protein Assay Kit (Thermo-Fisher-Scientific).
Approximately 20 µg of proteins were resolved by 10% or 12% SDS-PAGE and they were then transferred to a nitro cellulose membrane (Hybond-ECL, Amersham
Biosciences Taq (Takara). The primers used for each reaction are indicated in Table S5 . Gene expression was quantified by the delta-delta Ct method.
EGFR Sequencing of primary GBMs
To identify point EGFR mutations, cDNAs from the different cell lines were sequenced using the primers indicated in LGG cohorts were individually analyzed. Correlation values were independently calculated for IDH1 mutant or wild-type samples in the TCGA LGG cohort. ChIP-seq analysis using anti-CTCF antibody was performed from profiling in IDH1 mutant and wildtype glioma patient specimens and culture models (GSE70991). Briefly tdf files from GEO repository from both IDH1 mutant and wild-type samples were downloaded and visualized using IGV browser. CTCF occupancy at the CpG islands located from MAPT loci was visualized.
Statistical analysis
For bar graphs, the level of significance was determined by a two- 
